139 related articles for article (PubMed ID: 6377216)
1. Modified pharmacokinetics of I-asparaginase from E coli by formation of specific antibodies to I-Asparaginase of different immunoglobulin classes in children with acute lymphocytic leukemia.
Wahn V; Fabry U; Körholz D; Reinhardt D; Jürgens H; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):303-11. PubMed ID: 6377216
[TBL] [Abstract][Full Text] [Related]
2. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.
Cheung NK; Chau IY; Coccia PF
Am J Pediatr Hematol Oncol; 1986; 8(2):99-104. PubMed ID: 3526939
[TBL] [Abstract][Full Text] [Related]
3. [Formation of specific IgG antibodies in l-asparaginase treatment. Distribution of IgG subclasses].
Körholz D; Urbanek R; Nürnberger W; Jobke A; Göbel U; Wahn V
Monatsschr Kinderheilkd; 1987 Jun; 135(6):325-8. PubMed ID: 3475571
[TBL] [Abstract][Full Text] [Related]
4. [Immunological aspects in the L-asparaginase treatment of children with lymphoproliferative diseases].
Zajaçzkowski J; Halikowski B; Pituch A; Legutko L; Pajdak E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(1):21-8. PubMed ID: 58815
[TBL] [Abstract][Full Text] [Related]
5. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
[TBL] [Abstract][Full Text] [Related]
6. Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia.
Brueck M; Koerholz D; Nuernberger W; Juergens H; Goebel U; Wahn V
Dev Pharmacol Ther; 1989; 12(4):200-4. PubMed ID: 2504568
[TBL] [Abstract][Full Text] [Related]
7. Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.
Zajaczkowski J; Pituch A; Legutko L; Pajak E
Helv Paediatr Acta; 1976 Jan; 30(4-5):441-6. PubMed ID: 1060605
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
9. Immunological responses to L-asparaginase.
Peterson RG; Handschumacher RE; Mitchell MS
J Clin Invest; 1971 May; 50(5):1080-90. PubMed ID: 4101590
[TBL] [Abstract][Full Text] [Related]
10. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism.
Fabry U; Körholz D; Jürgens H; Göbel U; Wahn V
Pediatr Res; 1985 Apr; 19(4):400-8. PubMed ID: 3858789
[TBL] [Abstract][Full Text] [Related]
11. [Allergic reactions in treatment with L-asparaginase. Significance of specific IgE antibodies].
Körholz D; Wahn U; Jürgens H; Wahn V
Monatsschr Kinderheilkd; 1990 Jan; 138(1):23-5. PubMed ID: 2314401
[TBL] [Abstract][Full Text] [Related]
12. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
13. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
15. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Holland JF; Ohnuma T
Cancer Treat Rep; 1981; 65 Suppl 4():123-30. PubMed ID: 7049376
[TBL] [Abstract][Full Text] [Related]
17. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
[TBL] [Abstract][Full Text] [Related]
18. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
Albertsen BK; Schrøder H; Jakobsen P; Avramis VI; Müller HJ; Schmiegelow K; Carlsen NT
Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
[TBL] [Abstract][Full Text] [Related]
19. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
